UBS Group Reiterates “CHF 82” Price Target for Novartis (NOVN)

UBS Group set a CHF 82 target price on Novartis (VTX:NOVN) in a report released on Wednesday morning, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the stock.

A number of other research firms also recently weighed in on NOVN. Deutsche Bank set a CHF 89 price target on Novartis and gave the stock a neutral rating in a research note on Friday, September 28th. Baader Bank set a CHF 89 price target on Novartis and gave the stock a buy rating in a research note on Friday, October 12th. JPMorgan Chase & Co. set a CHF 87 price target on Novartis and gave the stock a neutral rating in a research note on Tuesday, October 16th. Goldman Sachs Group set a CHF 110 price target on Novartis and gave the stock a buy rating in a research note on Monday, November 19th. Finally, HSBC set a CHF 84 price target on Novartis and gave the stock a neutral rating in a research note on Thursday, October 25th. Ten analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of CHF 90.60.

Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Story: Market Capitalization

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply